Skip to main content
. 2013 Mar 1;33(5):984–990. doi: 10.1007/s10875-013-9876-3

Fig. 3.

Fig. 3

Serum IgG levels reported in an EU study in PID patients switched from other SCIG products to equivalent doses of Hizentra®. Mean (n = 19) serum IgG concentration measured 3–6 months before switching from other SCIG products (Vivaglobin®, Subcuvia® or Gammanorm®) to Hizentra® was not different from that measured during 16 weeks of Hizentra® treatment. Error bars represent SD